Nasal septum perforation and bevacizumab

Medical Oncology

Volumn 28, Issue 1, 2011, Pages 89-93

  Power, Derek G ^a   Kemeny, Nancy E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bevacizumab; Breast cancer; Colorectal cancer; Nasal septum perforation; Ovarian cancer; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DEXAMETHASONE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ABDOMINAL DISCOMFORT; ABNORMAL FECES COMPOSITION; ADULT; AGED; ANAMNESIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; COLON ADENOCARCINOMA; COLONOSCOPY; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LIVER METASTASIS; LUNG METASTASIS; MALE; NOSE CONGESTION; NOSE SEPTUM PERFORATION; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; NASAL SEPTUM; NEOPLASMS; NOSE DISEASES; RUPTURE, SPONTANEOUS; TREATMENT OUTCOME;

EID: 79952245826     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-010-9464-9     Document Type: Article

References (30)

1. F Torino SM Corsello R Longo, et al. 2009 Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy Nat Rev Clin Oncol 6 219 228 19333228 10.1038/nrclinonc.2009.4 1:CAS:528: DC%2BD1MXktVCmtL4%3D
2. P LoRusso 2009 Toward evidence-based management of the dermatologic effects of EGFR inhibitors Oncology (Williston Park) 23 186 194
3. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 4938153 10.1056/NEJM197108122850711 1:STN:280: DyaE38%2FgvVCqsQ%3D%3D
4. N Ferrara HP Gerber J LeCouter 2003 The biology of VEGF and its receptors Nat Med 9 669 676 12778165 10.1038/nm0603-669 1:CAS:528:DC%2BD3sXktFOnur4%3D (Pubitemid 36749215)
5. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 15175435 10.1056/NEJMoa032691 1:CAS:528: DC%2BD2cXks1Gjt74%3D (Pubitemid 38702844)
6. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 17167137 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI (Pubitemid 44917502)
7. R Gray S Bhattacharya C Bowden, et al. 2009 Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer J Clin Oncol 27 4966 4972 19720913 10.1200/JCO.2008.21.6630 1:CAS:528:DC%2BD1MXhsVCrsr%2FJ
8. MH Cohen YL Shen P Keegan, et al. 2009 FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme Oncologist 14 1131 1138 19897538 10.1634/theoncologist.2009-0121 1:CAS:528:DC%2BC3cXjt1eqsw%3D%3D
9. B Escudier A Pluzanska P Koralewski, et al. 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103 2111 18156031 10.1016/S0140-6736(07)61904-7 (Pubitemid 350296300)
10. SA Cannistra UA Matulonis RT Penson, et al. 2007 Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 5180 5186 18024865 10.1200/JCO.2007.12.0782 1:CAS:528:DC%2BD2sXhsVKnsbzM (Pubitemid 350232248)
11. T Van den Wyngaert MT Huizing E Fossion, et al. 2009 Bisphosphonates in oncology: rising stars or fallen heroes Oncologist 14 181 191 19179412 10.1634/theoncologist.2008-0209
12. JS Ross D Madigan KP Hill, et al. 2009 Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance Arch Intern Med 169 1976 1985 19933959 10.1001/ archinternmed.2009.394
13. H Linda A von Heijne EO Major, et al. 2009 Progressive multifocal leukoencephalopathy after natalizumab monotherapy N Engl J Med 361 1081 1087 19741229 10.1056/NEJMoa0810316 1:CAS:528:DC%2BD1MXhtFart77J
14. CH Chung B Mirakhur E Chan, et al. 2008 Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1, 3-galactose N Engl J Med 358 1109 1117 18337601 10.1056/NEJMoa074943 1:CAS:528:DC%2BD1cXjt1aitLk%3D (Pubitemid 351398485)
15. Genentech: http://www.gene.com/gene/products/information/oncology/ avastin/ (2009). Accessed Nov 26th 2009.
16. S Hapani D Chu S Wu 2009 Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis Lancet Oncol 10 559 568 19482548 10.1016/S1470-2045(09)70112-3 1:CAS:528:DC%2BD1MXms12jtbk%3D
17. SM Gressett SR Shah 2009 Intricacies of bevacizumab-induced toxicities and their management Ann Pharmacother 43 490 501 19261963 10.1345/aph.1L426 1:CAS:528:DC%2BD1MXkt12nsLY%3D
18. GH Lyman AA Khorana 2009 Cancer, clots and consensus: new understanding of an old problem J Clin Oncol 27 4821 4826 19752337 10.1200/JCO.2009.22.3032 1:CAS:528:DC%2BD1MXhtlKjtLrL
19. M Kozloff MU Yood J Berlin, et al. 2009 Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study Oncologist 14 862 870 19726453 10.1634/theoncologist. 2009-0071 1:CAS:528:DC%2BD1MXhtlGgu77L
20. WJ van Heeckeren J Ortiz MM Cooney, et al. 2007 Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 25 2993 2995 17634476 10.1200/JCO.2007.11.5113 (Pubitemid 47218042)
21. P Glusker L Recht B Lane 2006 Reversible posterior leukoencephalopathy syndrome and bevacizumab N Engl J Med 354 980 982 16510760 10.1056/NEJMc052954 1:CAS:528:DC%2BD28XitVeqsLc%3D Discussion 980-982
22. N Bhattacharyya 2007 Clinical symptomatology and paranasal sinus involvement with nasal septal perforation Laryngoscope 117 691 694 17415140 10.1097/01.mlg.0000256455.01473.72 (Pubitemid 46559049)
23. Diamantopoulos, II NS Jones 2001 The investigation of nasal septal perforations and ulcers J Laryngol Otol 115 541 544 11485583 (Pubitemid 32673253)
24. SL Lee D Neskey J Mouzakes 2009 Potential predisposition for nasal septal perforation with methotrexate use: report of 2 cases and literature review Ear Nose Throat J 88 E12 E14 19688702
25. TH Tan B Stevenson D Yip 2006 Docetaxel-induced nasal septal perforation Intern Med J 36 471 472 16780459 10.1111/j.1445-5994.2006.01105.x 1:STN:280:DC%2BD28zms12qtQ%3D%3D (Pubitemid 43876246)
26. CM Burkart JJ Grisel DB Hom 2008 Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy Laryngoscope 118 1539 1541 18622319 10.1097/MLG.0b013e31817c4296 1:CAS:528:DC%2BD1cXhtVGnsL3P
27. AP Marin AR Sanchez EE Arranz 2009 Nasal septum perforation in a breast cancer patient treated with bevacizumab Ann Oncol 20 1901 1902 19752003 10.1093/annonc/mdp451
28. N Ruiz C Fernandez-Martos I Romero, et al. 2007 Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer J Clin Oncol 25 3376 3377 17664487 10.1200/JCO.2007.12.0006 (Pubitemid 47325627)
29. TA Traina L Norton K Drucker, et al. 2006 Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer Oncologist 11 1070 1071 17110625 10.1634/theoncologist.11-10-1070 (Pubitemid 44788397)
30. MG Fakih JC Lombardo 2006 Bevacizumab-induced nasal septum perforation Oncologist 11 85 86 16401718 10.1634/theoncologist.11-1-85 (Pubitemid 43152691)